| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
[Background and Aim] The risk of incidence of colorectal cancer in Crohn's disease is high. On the other hand, TNF-a inhibitors are frequently used for the treatment of Crohn's disease. There may be a risks for cancer emergence by using anti TNF-a drugs, but it is still controversial. The aim of the present study was to investigate the effect of anti TNF-a antibody for growth of colorectal cancer.
[Materials and Method] We used colon cancer cell lines (COLO205, DLD1, HCT8, HCT116, HT29) and stimulate those cells with TNF-a, anti TNF-a antibody. Proliferation was determined by using CCK-8 assay.
[Results and Conclusions] TNF-a reduced growth of colon cancer cells, while blockage of TNF-a by anti TNF-a antibody reduced progression of colon cancer cells. Thus, TNF-a plays a profound role in malignancy of colorectal cancer, and inhibition of TNF-a represents a promising therapeutic option.
|
